Prediction of the Risk of Placental Vascular Pathology and Venous Thromboembolic Disease (AngioPred)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Venous thromboembolic (VTE) disease is the first cause of maternal mortality in the world. Some other pregnancy pathologies called Placental Vascular Pathologies (PVP) are linked to VTE by biological thrombophilia and are the principal cause of perinatal mortality. the identification of predictive factors of risk of occurrence or recurrence of two pathologies could enable us to propose an appropriate monitoring of patients at risk.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
16 Years to 50 Years (Child, Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
previous history of one or more PVC episodes (preeclampsia, HELLPs, retroplacental hematoma, vascular IUGR<10th percentile, recurrence miscarriage >2, unexplained IUFD or IUFD after abruption placentae, eclampsia.
Previous history of personal VTE
Diabete (treated with diet or insulin)
chronic renal pathology
early and late pregnancy (<18 years, >38 years)
family history of cardiovascular disease of VTE
known biological thrombophilia without any personal past history of PVC or VTE
past history of in utero fetal death due to congenital malformations, rhesus incompatibility or an infection
previous history of IUGR which etiology was a chromosomal, genic or infectious anomaly